A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single/Multiple-dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BGM0504 Tablets Orally Administered in Healthy and Non-diabetic Overweight or Obese Chinese Subjects.
Latest Information Update: 02 Dec 2025
At a glance
- Drugs BGM 0504 (Primary)
- Indications Overweight
- Focus Adverse reactions
Most Recent Events
- 02 Dec 2025 New trial record